The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
 
Sara M. Tolaney
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celldex; Eisai; G1 Therapeutics; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; Paxman; Pfizer; Puma Biotechnology; Sanofi; Seagen; Silverback Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Irfan Cicin
Consulting or Advisory Role - Abbvie (Inst); Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Nobelpharma (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Teva
Speakers' Bureau - Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Rafael Betancourt
No Relationships to Disclose
 
Arlene Chan
Honoraria - Amgen; Eisai; Novartis
Consulting or Advisory Role - Lilly; Pfizer; Specialised Therapeutics
Speakers' Bureau - Prime Oncology
Research Funding - Eisai
Travel, Accommodations, Expenses - Amgen
 
Diego Kaen
Speakers' Bureau - Novartis; Pfizer; Roche
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen
Honoraria - Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech
Speakers' Bureau - Lilly; Teva
Research Funding - Eisai (Inst); Lilly (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Macrogenics; Polyphor
 
Suzette Delaloge
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Qianying Liu
Employment - Sanofi
Stock and Other Ownership Interests - Gilead Sciences; Sanofi
 
Sylvaine Cartot-Cotton
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Amele Amrate
Employment - Sanofi
 
Vasiliki Pelekanou
Employment - Sanofi
 
Katharine Ellen Cuff
Stock and Other Ownership Interests - Sonic Healthcare (I)
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Roche